Patents by Inventor Meike Hutt

Meike Hutt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11008402
    Abstract: The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 18, 2021
    Inventors: Roland Kontermann, Lisa Schmitt, Meike Hutt, Oliver Seifert, Monilola Olayioye, Michael Hust, Stefan Dübel, Jonas Zantow
  • Publication number: 20210101975
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 8, 2021
    Inventors: Felix UNVERDORBEN, Sebastian BUNK, Martin HOFMANN, Dominik MAURER, Meike HUTT, Claudia WAGNER, Leonie ALTEN
  • Publication number: 20210048442
    Abstract: The present invention relates to a method for the characterization of peptide:MHC binding polypeptides, e.g. by mass spectrometry and an analysis of the recognized peptide space, i.e. in order to identify peptides that can be bound in the context of their presentation by MHC, and those who cannot be bound.
    Type: Application
    Filed: August 11, 2020
    Publication date: February 18, 2021
    Inventors: Heiko SCHUSTER, Meike HUTT, Toni WEINSCHENK, Sebastian BUNK, Oliver SCHOOR, Linus BACKERT, Martin HOFMANN, Jens FRITSCHE, Felix UNVERDORBEN, Gisela SCHIMMACK, Florian SALOPIATA
  • Publication number: 20210032361
    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Meike HUTT, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER, Martin HOFMANN, Gabriele PSZOLLA, Sara YOUSEF, Claudia WAGNER, Frank SCHWOEBEL, Heiko SCHUSTER
  • Publication number: 20210032370
    Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Felix UNVERDORBEN, Meike HUTT, Dominik MAURER, Sebastian BUNK
  • Patent number: 10889645
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Felix Unverdorben, Sebastian Bunk, Martin Hofmann, Dominik Maurer, Meike Hutt, Claudia Wagner, Leonie Alten
  • Publication number: 20200207849
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 2, 2020
    Inventors: Felix UNVERDORBEN, Sebastian BUNK, Martin HOFMANN, Dominik MAURER, Meike HUTT, Claudia WAGNER, Leonie ALTEN
  • Patent number: 10618956
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 14, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Felix Unverdorben, Sebastian Bunk, Martin Hofmann, Dominik Maurer, Meike Hutt, Claudia Wagner, Leonie Alten
  • Patent number: 10428149
    Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 1, 2019
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Ugur Sahin, Roland Kontermann, Klaus Pfizenmaier, Martin Siegemund, Meike Hutt, Oliver Seifert
  • Patent number: 10428120
    Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: October 1, 2019
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt
  • Publication number: 20190135914
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: November 5, 2018
    Publication date: May 9, 2019
    Inventors: Felix UNVERDORBEN, Sebastian BUNK, Martin HOFMANN, Dominik MAURER, Meike HUTT, Claudia WAGNER, Leonie ALTEN
  • Publication number: 20180094059
    Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector.
    Type: Application
    Filed: March 18, 2016
    Publication date: April 5, 2018
    Inventors: Ugur SAHIN, Roland KONTERMANN, Klaus PFIZENMAIER, Martin SIEGEMUND, Meike HUTT, Oliver SEIFERT
  • Publication number: 20170145062
    Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.
    Type: Application
    Filed: January 19, 2017
    Publication date: May 25, 2017
    Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt
  • Publication number: 20140220017
    Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 7, 2014
    Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt